[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Topotecan.]
[J01GA01, streptomycin, Topotecan may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Topotecan.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Topotecan.]
[L04AA27, fingolimod, Topotecan may increase the immunosuppressive activities of Fingolimod.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01CG01, sulbactam, Topotecan may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Topotecan.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Topotecan.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AX03, sulthiame, Sulthiame may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Topotecan is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The serum concentration of Topotecan can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Topotecan.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, The serum concentration of Topotecan can be increased when it is combined with Dabigatran etexilate.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Topotecan.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Topotecan is combined with Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Topotecan is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Topotecan is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Topotecan.]
[N05CA19, thiopental, Thiopental may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE06, moxisylyte, Topotecan may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Topotecan may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Topotecan.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01AA12, tobramycin, Topotecan may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[V04CA01, tolbutamide, Topotecan may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Topotecan.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Topotecan.]
[N06AX05, trazodone, The serum concentration of Topotecan can be decreased when it is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Topotecan.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Topotecan.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Topotecan may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Topotecan.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Topotecan is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Topotecan.]
[A03AA05, trimebutine, Topotecan may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[N03AC02, trimethadione, Trimethadione may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EA01, trimethoprim, The excretion of Topotecan can be decreased when combined with Trimethoprim.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Topotecan.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Belimumab.]
[L01FX04, ipilimumab, Topotecan may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The serum concentration of Topotecan can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Topotecan may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The serum concentration of Topotecan can be increased when it is combined with Linagliptin.]
[J05AP02, telaprevir, The serum concentration of Topotecan can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Topotecan.]
[S01AA28, vancomycin, Topotecan may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Topotecan is combined with Belatacept.]
[N03AX21, ezogabine, Ezogabine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, The serum concentration of Topotecan can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Topotecan can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Topotecan can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Topotecan can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, Topotecan may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Topotecan.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Topotecan.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Topotecan.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Topotecan.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Topotecan.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Topotecan.]
[N03AX14, levetiracetam, Levetiracetam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC01, vemurafenib, The serum concentration of Topotecan can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Topotecan is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, Topotecan may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Topotecan may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Topotecan can be increased when it is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Topotecan may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Topotecan.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Topotecan.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Topotecan is combined with Ruxolitinib.]
[G04BD07, tolterodine, Topotecan may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Topotecan may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Topotecan.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Topotecan.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[R07AX02, ivacaftor, The serum concentration of Topotecan can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Topotecan is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Topotecan.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Topotecan.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Topotecan.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Topotecan.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Topotecan.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan.]
[A08AA11, lorcaserin, Topotecan may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The serum concentration of Topotecan can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Topotecan can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Topotecan can be increased when it is combined with Cobicistat.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Topotecan.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Topotecan is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Topotecan is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Topotecan.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Topotecan is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Topotecan is combined with Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Topotecan can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, Barbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[D02BA02, octinoxate, Topotecan may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Topotecan is combined with Bendamustine.]
[N04BD02, rasagiline, Topotecan may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AX22, perampanel, Perampanel may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Topotecan.]
[V09IX04, fluorodeoxyglucose F18, Topotecan may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[G04BE03, sildenafil, The serum concentration of Topotecan can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Topotecan may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The serum concentration of Topotecan can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Topotecan can be increased when it is combined with Apixaban.]
[A16AX08, teduglutide, Topotecan may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The serum concentration of Topotecan can be increased when it is combined with Lomitapide.]
[A10BH04, alogliptin, Topotecan may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Topotecan may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Topotecan is combined with Pomalidomide.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A10BK02, canagliflozin, The serum concentration of Topotecan can be increased when it is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Topotecan is combined with Dimethyl fumarate.]
[A06AX06, tegaserod, The serum concentration of Topotecan can be increased when it is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Benzocaine.]
[L03AA12, ancestim, Topotecan may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA18, everolimus, The serum concentration of Topotecan can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01EC02, dabrafenib, Dabrafenib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01EE01, trametinib, Topotecan may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Topotecan may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Topotecan can be increased when it is combined with Afatinib.]
[N06AX28, levomilnacipran, Topotecan may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Topotecan can be increased when it is combined with Dolutegravir.]
[C02KX05, riociguat, The serum concentration of Topotecan can be increased when it is combined with Riociguat.]
[L03AA14, lipegfilgrastim, Topotecan may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, Topotecan may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Topotecan may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Topotecan.]
[N06AX26, vortioxetine, Topotecan may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP05, simeprevir, The serum concentration of Topotecan can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Topotecan can be increased when it is combined with Sofosbuvir.]
[N03AG04, vigabatrin, Vigabatrin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Topotecan may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Topotecan may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Topotecan is combined with Apremilast.]
[L02BG02, formestane, Topotecan may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Topotecan.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Topotecan.]
[V03AB34, fomepizole, Topotecan may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Topotecan is combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Topotecan can be increased when it is combined with Ceritinib.]
[B01AC26, vorapaxar, The serum concentration of Topotecan can be increased when it is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Topotecan.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Topotecan is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Topotecan is combined with Idelalisib.]
[N07XX08, tafamidis, The serum concentration of Topotecan can be increased when it is combined with Tafamidis.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Topotecan is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05CM19, suvorexant, The serum concentration of Topotecan can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Topotecan.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Topotecan is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Topotecan is combined with Pirfenidone.]
[L01EX09, nintedanib, The serum concentration of Topotecan can be increased when it is combined with Nintedanib.]
[S03AA06, gentamicin, Topotecan may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Topotecan is combined with Blinatumomab.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Topotecan is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Topotecan.]
[B01AF03, edoxaban, The serum concentration of Topotecan can be increased when it is combined with Edoxaban.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Topotecan can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Topotecan can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Topotecan is combined with Panobinostat.]
[J05AP07, daclatasvir, The serum concentration of Topotecan can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Topotecan.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Topotecan.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AP06, asunaprevir, The serum concentration of Topotecan can be increased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Topotecan.]
[A04AD14, rolapitant, The serum concentration of Topotecan can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Topotecan can be increased when it is combined with Flibanserin.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[V03AB37, idarucizumab, Topotecan may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Topotecan is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Mepolizumab.]
[J02AC05, isavuconazole, The serum concentration of Topotecan can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, Osimertinib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Topotecan.]
[L01EE02, cobimetinib, The serum concentration of Topotecan can be increased when it is combined with Cobimetinib.]
[L01XG03, ixazomib, Topotecan may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AC27, selexipag, The serum concentration of Topotecan can be increased when it is combined with Selexipag.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Topotecan.]
[M04AB05, lesinurad, Topotecan may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[L01XA04, satraplatin, The risk or severity of adverse effects can be increased when Satraplatin is combined with Topotecan.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AX23, brivaracetam, Brivaracetam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Topotecan can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, Topotecan may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Topotecan may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Bupivacaine.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Topotecan.]
[L01XX27, arsenic trioxide, The serum concentration of Topotecan can be increased when it is combined with Arsenic trioxide.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Brodalumab.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Topotecan.]
[A06AH05, naldemedine, Topotecan may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Topotecan may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX30, beclamide, Beclamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Topotecan may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Topotecan.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Topotecan.]
[J05AF06, abacavir, Topotecan may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The serum concentration of Topotecan can be increased when it is combined with Tipranavir.]
[N07XX13, valbenazine, Topotecan may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Topotecan.]
[L01ED04, brigatinib, The excretion of Topotecan can be decreased when combined with Brigatinib.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Sarilumab.]
[J01MA23, delafloxacin, Topotecan may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The serum concentration of Topotecan can be increased when it is combined with Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Topotecan is combined with Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Topotecan can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Topotecan can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Topotecan can be increased when it is combined with Inotuzumab ozogamicin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Topotecan is combined with Vorinostat.]
[L01EM02, copanlisib, The excretion of Topotecan can be decreased when combined with Copanlisib.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Topotecan.]
[C07AB07, bisoprolol, The serum concentration of Topotecan can be increased when it is combined with Bisoprolol.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Topotecan.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Topotecan.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Topotecan.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Topotecan is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Topotecan.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Topotecan may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, The serum concentration of Topotecan can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, Carbamazepine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Topotecan.]
[C07AG02, carvedilol, The serum concentration of Topotecan can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Topotecan is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01GB14, plazomicin, The excretion of Topotecan can be decreased when combined with Plazomicin.]
[H01CC03, elagolix, The serum concentration of Topotecan can be increased when it is combined with Elagolix.]
[P01BA07, tafenoquine, The excretion of Topotecan can be decreased when combined with Tafenoquine.]
[A16AX14, migalastat, Topotecan may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The excretion of Topotecan can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Topotecan can be increased when it is combined with Lusutrombopag.]
[L01EM04, duvelisib, The serum concentration of Topotecan can be increased when it is combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Topotecan can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Topotecan can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Topotecan can be increased when it is combined with Omadacycline.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Topotecan may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XK04, talazoparib, The serum concentration of Topotecan can be increased when it is combined with Talazoparib.]
[R03BB08, revefenacin, The serum concentration of Topotecan can be increased when it is combined with Revefenacin.]
[L01ED05, lorlatinib, The serum concentration of Topotecan can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Topotecan.]
[L01EX12, larotrectinib, The serum concentration of Topotecan can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The excretion of Topotecan can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Topotecan can be increased when it is combined with Glasdegib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Topotecan.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Topotecan.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Topotecan.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Topotecan is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Topotecan can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, The excretion of Topotecan can be decreased when combined with Solriamfetol.]
[N06AX29, brexanolone, Brexanolone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EN01, erdafitinib, The serum concentration of Topotecan can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, Clobazam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Topotecan is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Topotecan.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Topotecan is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Risankizumab.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Topotecan can be increased when it is combined with Darolutamide.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01EX15, pexidartinib, The excretion of Topotecan can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Topotecan is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Topotecan can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Topotecan can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, Topotecan may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[J01XX12, lefamulin, The serum concentration of Topotecan can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The serum concentration of Topotecan can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX09, daptomycin, The serum concentration of Topotecan can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The excretion of Topotecan can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DB09, cephradine, The excretion of Topotecan can be decreased when combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Topotecan is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Topotecan.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Topotecan is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, The serum concentration of Topotecan can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Topotecan is combined with Diroximel fumarate.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Topotecan.]
[N03AX25, cenobamate, Cenobamate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M09AX08, golodirsen, Topotecan may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Topotecan can be increased when it is combined with Ubrogepant.]
[L01FX13, enfortumab vedotin, The serum concentration of Topotecan can be increased when it is combined with Enfortumab vedotin.]
[S01XA12, dexpanthenol, Topotecan may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N05CM21, lemborexant, The serum concentration of Topotecan can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The excretion of Topotecan can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Teprotumumab.]
[N02CD06, rimegepant, The serum concentration of Topotecan can be increased when it is combined with Rimegepant.]
[J05AB16, remdesivir, The excretion of Topotecan can be decreased when combined with Remdesivir.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Topotecan is combined with Ozanimod.]
[L01EE04, selumetinib, The serum concentration of Topotecan can be increased when it is combined with Selumetinib.]
[R02AA03, dichlorobenzyl alcohol, Topotecan may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Topotecan may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Topotecan.]
[C08CA16, clevidipine, Topotecan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The serum concentration of Topotecan can be increased when it is combined with Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Topotecan.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Topotecan.]
[L01EH03, tucatinib, The serum concentration of Topotecan can be increased when it is combined with Tucatinib.]
[L01EX17, capmatinib, The serum concentration of Topotecan can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Topotecan is combined with Fluprednidene.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01EX19, ripretinib, The serum concentration of Topotecan can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, Topotecan may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The excretion of Topotecan can be decreased when combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05CM02, chlormethiazole, Clomethiazole may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Topotecan is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Topotecan is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Topotecan.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, The serum concentration of Topotecan can be increased when it is combined with Belantamab mafodotin.]
[M09AX10, risdiplam, The serum concentration of Topotecan can be increased when it is combined with Risdiplam.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Satralizumab.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01EX23, pralsetinib, The serum concentration of Topotecan can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02BA03, choline salicylate, Topotecan may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Vinpocetine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B06AC06, berotralstat, The serum concentration of Topotecan can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Topotecan can be increased when it is combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Topotecan is combined with Fludarabine.]
[L02BX04, relugolix, The serum concentration of Topotecan can be increased when it is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Topotecan may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The serum concentration of Topotecan can be increased when it is combined with Voclosporin.]
[L01EX21, tepotinib, The serum concentration of Topotecan can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Topotecan can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The excretion of Topotecan can be decreased when combined with Trilaciclib.]
[N03AX10, felbamate, Felbamate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Topotecan.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Topotecan.]
[N02BG07, flupirtine, Topotecan may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Topotecan is combined with Ponesimod.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Topotecan.]
[L01FX22, loncastuximab tesirine, The serum concentration of Topotecan can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, The excretion of Topotecan can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XX73, sotorasib, The serum concentration of Topotecan can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The excretion of Topotecan can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Topotecan is combined with Pegcetacoplan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Topotecan.]
[L04AA48, belumosudil, The serum concentration of Topotecan can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The excretion of Topotecan can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Anifrolumab.]
[V09AB03, ioflupane I-123, Topotecan may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Topotecan may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Topotecan can be increased when it is combined with Technetium Tc-99m sestamibi.]
[V09AX06, florbetaben f-18, Topotecan may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[N06AX25, St. John's wort extract, The serum concentration of Topotecan can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Topotecan can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Topotecan can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Topotecan is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The serum concentration of Topotecan can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Topotecan can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Topotecan.]
[B06AX04, mitapivat, The serum concentration of Topotecan can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Topotecan can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Topotecan can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, Topotecan may decrease the excretion rate of Clomipramine which could result in a higher serum level.]
[N03AE01, clonazepam, Clonazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J02AC06, oteseconazole, The serum concentration of Topotecan can be increased when it is combined with Oteseconazole.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Topotecan is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Topotecan is combined with Deucravacitinib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Topotecan is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Topotecan can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Topotecan can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, Topotecan may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Topotecan.]
[J01XB01, colistin, Topotecan may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Topotecan is combined with Leflunomide.]
[A04AA03, tropisetron, Topotecan may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, Ifenprodil may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Topotecan is combined with Nelarabine.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Topotecan is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Topotecan.]
[J05AB14, valganciclovir, Topotecan may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[J05AF09, emtricitabine, The excretion of Topotecan can be decreased when combined with Emtricitabine.]
[C05BB03, invert sugar, Topotecan may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Topotecan may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Topotecan may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Topotecan may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Topotecan may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J02AC02, itraconazole, The serum concentration of Topotecan can be increased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Topotecan.]
[S01AD03, acyclovir, The excretion of Topotecan can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, Topotecan may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Topotecan.]
[J02AC04, posaconazole, The serum concentration of Topotecan can be increased when it is combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Topotecan.]
[N03AX09, lamotrigine, Lamotrigine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N07BC04, lofexidine, The excretion of Topotecan can be decreased when combined with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Topotecan may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Topotecan is combined with Meprednisone.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Topotecan may decrease the excretion rate of Melperone which could result in a higher serum level.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Topotecan.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, The serum concentration of Topotecan can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Topotecan.]
[S01XA18, cyclosporine, Topotecan may increase the immunosuppressive activities of Cyclosporine.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03XA02, conivaptan, The serum concentration of Topotecan can be increased when it is combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Topotecan.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Topotecan.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Topotecan.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Topotecan.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Topotecan.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N07BB05, nalmefene, Topotecan may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06AX06, nefazodone, Topotecan may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Topotecan may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AG06, tiagabine, Tiagabine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Topotecan.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06AA01, desipramine, Topotecan may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Topotecan.]
[V04CH02, indigo carmine, Topotecan may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Topotecan.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Topotecan is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Topotecan.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AC01, paramethadione, Paramethadione may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Topotecan.]
[P03AC04, permethrin, Topotecan may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX07, phenacemide, Phenacemide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Phenol.]
[N03AD02, phensuximide, Phensuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Cinchocaine.]
[R05DA08, pholcodine, Topotecan may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01DC04, ixabepilone, The serum concentration of Topotecan can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, Erlotinib may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Topotecan is combined with Pirarubicin.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AA13, pegfilgrastim, The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Topotecan is combined with Difluocortolone.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C01AA04, digitoxin, The serum concentration of Topotecan can be increased when it is combined with Digitoxin.]
[C01AA05, digoxin, Topotecan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Topotecan.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Topotecan.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[H03BC01, potassium perchlorate, Topotecan may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Pramocaine.]
[V03AB09, dimercaprol, Topotecan may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Topotecan may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, Progabide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C05CA03, diosmin, The serum concentration of Topotecan can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Topotecan.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Topotecan.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Topotecan.]
[S01AX06, resorcinol, Topotecan may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab.]
[S02AA12, rifamycin SV, The serum concentration of Topotecan can be increased when it is combined with Rifamycin.]
[N07XX02, riluzole, Riluzole may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AE09, levocetirizine, Topotecan may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Topotecan.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Topotecan is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Topotecan.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C02KX02, ambrisentan, The serum concentration of Topotecan can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Topotecan can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06AA12, doxepin, Topotecan may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Topotecan.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A08AA10, sibutramine, Topotecan may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The serum concentration of Topotecan can be increased when it is combined with Simvastatin.]
[A12CA02, sodium sulfate, Topotecan may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Topotecan can be increased when it is combined with Talinolol.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Topotecan is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Topotecan.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06AG03, toloxatone, Topotecan may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA02, toremifene, The serum concentration of Topotecan can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Topotecan may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Topotecan.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Topotecan is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Topotecan is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Topotecan.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Topotecan.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Topotecan.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AX15, zonisamide, The serum concentration of Topotecan can be increased when it is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Topotecan.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Topotecan.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Topotecan.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Topotecan.]
[N03AG01, valproic acid, Valproic acid may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX05, pidotimod, Topotecan may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The serum concentration of Topotecan can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Topotecan is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Topotecan is combined with Fluticasone.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AD01, ethosuximide, Ethosuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AB01, ethotoin, Ethotoin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Topotecan.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Topotecan.]
[P01AX07, trimetrexate, Topotecan may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Topotecan may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Topotecan.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Topotecan may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Topotecan may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Topotecan.]
[A02BA03, famotidine, The excretion of Topotecan can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AX26, fenfluramine, Fenfluramine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Topotecan.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Topotecan.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Topotecan.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Topotecan.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[G04BD02, flavoxate, Topotecan may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The excretion of Topotecan can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J02AC01, fluconazole, The serum concentration of Topotecan can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Topotecan is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Topotecan.]
[V03AB25, flumazenil, Topotecan may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, Flunarizine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Topotecan is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Topotecan is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Topotecan.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Topotecan.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Topotecan.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Topotecan.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01BC03, tegafur, Topotecan may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[J05AE10, darunavir, The serum concentration of Topotecan can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Topotecan.]
[S01AD09, ganciclovir, The excretion of Topotecan can be decreased when combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AB04, gemfibrozil, Topotecan may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Topotecan may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Topotecan is combined with Dasatinib.]
[N03AD03, methsuximide, Methsuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EH01, lapatinib, The serum concentration of Topotecan can be increased when it is combined with Lapatinib.]
[A10BB07, glipizide, Topotecan may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01EX02, sorafenib, The serum concentration of Topotecan can be increased when it is combined with Sorafenib.]
[M01CB04, aurothioglucose, Topotecan may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Topotecan may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Topotecan.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01EX01, guanethidine, Topotecan may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Topotecan.]
[N05AH04, quetiapine, Topotecan may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Topotecan may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Topotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Topotecan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Topotecan.]
[G03DC01, allylestrenol, Topotecan may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Topotecan.]
[N05CA16, hexobarbital, Hexobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Topotecan.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C02DB02, hydralazine, Topotecan may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Topotecan is combined with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Topotecan may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[G04BD06, propiverine, Topotecan may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Topotecan is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Topotecan may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Topotecan.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B05XA08, sodium acetate, Topotecan may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Topotecan.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Topotecan is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Topotecan is combined with Ifosfamide.]
[N06AA02, imipramine, Imipramine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Topotecan is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Topotecan is combined with Tixocortol.]
[M03BX02, tizanidine, Tizanidine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Topotecan is combined with Antilymphocyte immunoglobulin (horse).]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Topotecan may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Topotecan is combined with Fluticasone furoate.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Topotecan.]
[A11HA07, inositol, Topotecan may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Topotecan.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Topotecan.]
[N06AX17, milnacipran, Topotecan may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Topotecan may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Topotecan can be increased when it is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Topotecan.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Topotecan.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Topotecan.]
[V03AB01, ipecac, Topotecan may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AX05, inosine pranobex, Topotecan may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Topotecan.]
[S01AA24, kanamycin, Topotecan may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Tocilizumab.]
[N01AX03, ketamine, Topotecan may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Topotecan.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Topotecan.]
[J02AB02, ketoconazole, The serum concentration of Topotecan can be increased when it is combined with Ketoconazole.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Topotecan is combined with Abatacept.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A06AX03, lubiprostone, Topotecan may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, Lacosamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Topotecan.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Lidocaine.]
[S01AA21, amikacin, Topotecan may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Topotecan.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Topotecan is combined with Lomustine.]
[A07DA03, loperamide, The serum concentration of Topotecan can be increased when it is combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Topotecan.]
[N05AH01, loxapine, The serum concentration of Topotecan can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Topotecan can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Topotecan may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Topotecan may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Topotecan is combined with Pralatrexate.]
[L01EA03, nilotinib, The serum concentration of Topotecan can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Topotecan.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05BA03, medazepam, Medazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BC02, mefloquine, The serum concentration of Topotecan can be increased when it is combined with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Topotecan.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Topotecan.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Topotecan.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Topotecan is combined with Melphalan.]
[N06DX01, memantine, Topotecan may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AB04, mephenytoin, Mephenytoin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Mepivacaine.]
[G04BX16, tiopronin, Topotecan may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, The serum concentration of Topotecan can be increased when it is combined with Paliperidone.]
[A10BA02, metformin, The excretion of Topotecan can be decreased when combined with Metformin.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06BA03, methamphetamine, Topotecan may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AA30, metharbital, Metharbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Topotecan.]
[L03AA02, filgrastim, The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Topotecan.]
[N05CA15, methohexital, Methohexital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Topotecan.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[V04CG05, methylene blue, The serum concentration of Topotecan can be increased when it is combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Topotecan.]
[N03AF03, rufinamide, Rufinamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[G03EK01, methyltestosterone, Topotecan may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, Topotecan may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Topotecan.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Topotecan.]
[G03XB01, mifepristone, The serum concentration of Topotecan can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Topotecan.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Topotecan is combined with Mitoxantrone.]
[L03AA10, lenograstim, The risk or severity of neutropenia can be increased when Lenograstim is combined with Topotecan.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Topotecan.]
[C01BD01, amiodarone, The serum concentration of Topotecan can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02AA01, morphine, The serum concentration of Topotecan can be increased when it is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Topotecan is combined with Certolizumab pegol.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[G04BA01, ammonium chloride, Topotecan may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Topotecan is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Topotecan.]
[N05CA02, amobarbital, Amobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[G04CA04, silodosin, The serum concentration of Topotecan can be increased when it is combined with Silodosin.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Topotecan.]
[C07AA12, nadolol, The excretion of Topotecan can be decreased when combined with Nadolol.]
[J01CA04, amoxicillin, Topotecan may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Topotecan may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Topotecan.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Topotecan.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Topotecan is combined with Docetaxel.]
[S03AA01, neomycin, Topotecan may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Topotecan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Topotecan.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L03AX16, plerixafor, Topotecan may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Topotecan may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Topotecan may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Topotecan can be decreased when combined with Febuxostat.]
[C01CE01, inamrinone, Topotecan may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Topotecan.]
[C08CA05, nifedipine, Topotecan may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05CD02, nitrazepam, Nitrazepam may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A16AX07, sapropterin, The serum concentration of Topotecan can be increased when it is combined with Sapropterin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Topotecan.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Topotecan.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Topotecan is combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N02AA02, opium, Topotecan may decrease the excretion rate of Opium which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Topotecan.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Topotecan.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Topotecan.]
[J04AB30, capreomycin, Topotecan may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, Paraldehyde may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Topotecan is combined with Paramethasone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[G04BD11, fesoterodine, Topotecan may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Topotecan may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Topotecan.]
[J01CE09, penicillin G procaine, Topotecan may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Topotecan.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Topotecan.]
[N05CA01, pentobarbital, Pentobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Topotecan.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Topotecan.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Topotecan.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Topotecan.]
[N03AA02, phenobarbital, Phenobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Topotecan.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N03AB02, phenytoin, Phenytoin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Golimumab.]
[S01AE05, levofloxacin, The excretion of Topotecan can be decreased when combined with Levofloxacin.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C08CX01, mibefradil, The serum concentration of Topotecan can be increased when it is combined with Mibefradil.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Topotecan.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J05AE01, saquinavir, The serum concentration of Topotecan can be increased when it is combined with Saquinavir.]
[N06BX03, piracetam, Topotecan may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Topotecan.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Topotecan.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Topotecan can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Topotecan may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Topotecan.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Topotecan.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Prilocaine.]
[N03AA03, primidone, Primidone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[M04AB01, probenecid, Topotecan may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, The excretion of Procainamide can be decreased when combined with Topotecan.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Topotecan is combined with Procarbazine.]
[C10AB05, fenofibrate, Topotecan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[R06AD02, promethazine, Topotecan may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[C01BC03, propafenone, The serum concentration of Topotecan can be increased when it is combined with Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[R06AX26, fexofenadine, The serum concentration of Topotecan can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The serum concentration of Topotecan can be increased when it is combined with Romidepsin.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Topotecan.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Topotecan.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Topotecan.]
[N07XX07, dalfampridine, Topotecan may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Topotecan may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Topotecan.]
[P01BD01, pyrimethamine, The excretion of Topotecan can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The serum concentration of Topotecan can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Topotecan can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C02AA02, reserpine, The serum concentration of Topotecan can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Topotecan can be decreased when it is combined with Rifampicin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Topotecan.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[N05CA06, secobarbital, Secobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Topotecan is combined with Obinutuzumab.]
[J01GB08, sisomicin, Topotecan may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Topotecan may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Topotecan.]
[V04CC01, sorbitol, Topotecan may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Topotecan is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Topotecan.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[H02CA04, levoketoconazole, The serum concentration of Topotecan can be increased when it is combined with Levoketoconazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
